Golotimod

• Description:

  Golotimod (SCV-07), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod (SCV-07) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod (SCV-07) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2) [1][2][3].

• Product Name Alternative:

  SCV 07; Gamma-D-glutamyl-L-tryptophan

• UNSPSC:

  12352209

• Target:

  Bacterial; STAT

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; JAK/STAT Signaling; Stem Cell/Wnt

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection; Inflammation/Immunology; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/golotimod.html

• Purity:

  98.04

• Solubility:

  DMSO : 50 mg/mL (ultrasonic) |H2O : 125 mg/mL (ultrasonic)

• Smiles:

  O=C(CC[C@@](N)(C(O)=O)[H])N[C@]([H])(C(O)=O)CC1=CNC2=C1C=CC=C2

• Molecular Formula:

  C16H19N3O5

• Molecular Weight:

  333.34

• References & Citations:

  [1]Rose WA 2nd, et al. An immunomodulating dipeptide, SCV-07, is a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2) . Int J Antimicrob Agents. 2008 Sep;32 (3) :262-6.|[2]Geiger JL, et al. The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. Oral Oncol. 2016 May;56:84-92.|[3]Watkins B, et al. Attenuation of radiation- and chemoradiation-induced mucositis using gamma-D-glutamyl-L-tryptophan (SCV-07) . Oral Dis. 2010 Oct;16 (7) :655-60.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, sealed storage, away from moisture and light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• Isoform:

  STAT3

• CAS Number:

  [229305-39-9]